The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA
Portfolio Pulse from
The Gross Law Firm has announced a securities class action lawsuit against Intellia Therapeutics, alleging that the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency. The lawsuit claims Intellia failed to disclose the declining relevance of viral-based editing and subsequently halted the program, leading to a stock price drop from $12.02 to $10.20 per share.
April 03, 2025 | 5:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Securities class action lawsuit alleges material misrepresentation about NTLA-3001 program, potentially impacting investor confidence and stock performance.
The lawsuit alleges material omissions about the NTLA-3001 program, which led to a stock price decline and could create investor uncertainty about the company's transparency and strategic decisions.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100